Osteoporosis: G. A. Rodan, discussion leader
G. A. Rodan, "Pathophysiology of Osteoporosis and the use of
Bisphosphonates."
J. D. Termine, "Estrogen Analogs in the Treatment and Prevention of
Osteoporosis."
T. K. Sampath, "Therapeutic Application of Bone Morphogenetic
Proteins."
J. Krstenansky, "Parathyroid Hormone and Analogs for Stimulation of
Bone Formation."
Structure-Based Drug Design: I. D. Kuntz, discussion leader
I. D. Kuntz, "Overview of Structure-Based Design."
R. DesJarlais, "Rational Design of HIV Protease Inhibitors."
S. Ealick, "Structure-Based Design of Purine Nucleoside Phosphorylase
Inhibitors."
M. Varney, "The Use of Protein Structure-Based Molecular Design as a
Tool in Drug Discovery."
Ras-Specific Inhibition: J. F. Hancock, discussion leader
J. F. Hancock, "Ras Signaling Pathways and Biology of Ras
Prenylation."
M. Gelb, "Biological Functions of Protein Prenyl Groups and the
Enzymology of the Prenylated Protein Maturation Pathway."
A. M. Garcia, "Isoprenyl Transferase Inhibition by Peptide Mimics."
J. B. Gibbs, "Farnesyl-Protein Transferase Inhibitors."
Blockade of Prostatic a1-Adrenoceptors: J. P. Hieble, discussion leader
J. P. Hieble, "Subclassification of the a1-Adrenoceptor via Functional,
Radioligand Binding and Molecular Techniques."
C. Gluchowski, "Design of Subtype Selective a1-Adrenoceptor
Antagonists as a Therapeutic Approach to BPH."
H. Lepor, "The Role of a1-Adrenoceptor Antagonists in BPH Therapy:
Potential Clinical Benefits from Subtype Selectively."
Tachykinin Receptor Antagonists: J.E. Krause, discussion leader
J. E. Krause, "An Overview of Tachykinin Receptors: From Molecular
Biology to Gene Regulation."
W. Schilling, "Approaches for the Design of Non-Peptide Antagonists:
Hypothesis vs. Reality."
C. J. Swain, "Novel Structural Classes of NK-1 Antagonists: SAR and
Modeling Studies."
R. Bell, "From Peptide Leads to Non-Peptide Drugs: GR 159897, a
Potent Orally Active Neurokinin NK-2 Receptor Antagonist."
Vascular Biology: F. Gaeta, discussion leader
J. Musser, "Glycomimetics Based on Sialyl Lewis X as Potential Anti-
Inflammatory Agents."
W. C. Ripka, "Design and Synthesis of Inhibitors of Coagulation Factor
Xa."
Drug Bioavailability: G. Amidon, discussion leader
G. Amidon, "Drug Transport and Transit in the Trolling GI Tract. Factors
on Oral Bioavailability."
P. Burton, "Lipophilicity and Hydrogen Bonding in Membrane Transport
and Drug Absorption."
B. Anderson, "Structure Transport Relationships in Bilayer
Biomembranes: Implications for Analog and Prodrug Design."
W. J. Greenlee, discussion leader
|
